Management

Michel Levesque, MD, C0-Founder and CEO

Michel LéMFL-Pic 2012vesque,MD, is the Founder and CEO, of Siragen Pharmaceuticals. A successful entrepreneur, neuroscientist and neurosurgeon, Dr Levesque is also  an Associate Clinical Professor of Neurosurgery at the UCLA School of Medicine, member of the UCLA Brain Research Institute. He is the Chairman of the Foundation for Neural Repair, a not-for-profit foundation, sponsoring translational research to accelerate human trials . Dr. Lévesque has authored over 75 articles in peer-reviewed professional journals, contributed chapters to many leading neurosurgery treatises, has published over 200 scientific abstracts, and inventor of 7 patents. Dr. Lévesque received his medical degree at Universite de Montreal and completed post-graduate studies in neurosciences, studying central nervous system regeneration at Mc Gill University under Dr Albert Aguayo. He completed his neurosurgical training at the Montreal Neurological Institute and Mc Gill University, and a fellowship in functional neurosurgery.

Mohamedi Kagalwala, PhD, MBA, Co-Founder and Chief Scientific Officer

IMG_6793 copyMohamedi “Mo” Kagalwala, PhD, MBA,  is the chief scientific officer at Siragen Pharmaceuticals.  Dr. Kagalwala is responsible for overseeing the research and development activities including discovery and pre-clinical studies with all assets in the pipeline. He is regarded as one of the pioneers in the field of chromatin and epigenetics for his contributions to chromatin remodeling. Dr. Kagalwala trained at Bhaba Atomic Research Center, Trombay, India and National Center for Biological Sciences, Bangalore, India.  Dr. Kagalwala was then offered a Research Associate position in neurobiology and neurodegenerative disorders at the Salk Institute in La Jolla, CA under  Prof. Fred “Rusty” Gage. There he expanded his knowledge and expertise of neural stem cells to understand adult neurogenesis in the hippocampus and carried out biochemical and functional genomic analysis of iPSC derived Neural Stem Cells from Schizophrenia patients.  There he laid the solid foundation for his research in the understanding the molecular mechanisms of aging and neurodegeneration.

Patricia Eastman, MHA ,Vice President Corporate Services

Patricia2

 

Patricia Eastman, MHA is Vice President Corporate Services at Siragen Pharmaceuticals. She has served as Senior Vice President for Corporate Affairs at Neurogeneration since 2008. She previously was CEO of Associated Students UCLA. Prior to this, she served as Vice President, Business Development, Cedars-Sinai Medical Center. She is a graduate of Arizona State University and Loma Linda University.

 

 

 

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s